Abstract A 78-year-old 
Introduction

Thrombotic microangiopathy (TMA) is a microvascular occlusive syndrome characterized by systemic aggregation of platelets, leading to ischemia in the kidneys and other organs (1). The laboratory characteristics of TMA include thrombocytopenia, microangiopathic hemolytic anemia, and extremely elevated serum levels of lactate dehydrogenase (LDH). Causes of TMA include thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), malignant hypertension, and certain medications. TMA is one of the complications of certain forms of rheumatic disease [eg, systemic lupus erythematosus
, systemic sclerosis, and overlap syndrome (3) ]. However, systemic vasculitis such as polyarteritis nodosa (PAN) (4, 5) 
